Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

eBay Inc (EBAY), Yahoo! Inc. (YHOO), Valeant Pharmaceuticals (VRX): Ivory Capital Continues to Perform Well in Relative Anonymity

Page 1 of 2

The founder of Ivory Capital, Curtis Macnguyen may have a bone to pick with his fellow hedge fund managers, whose investment skills might not be better than his own, though they enjoy the perks of greater assets under management partly as a result of being less private and more in the public eye.  In an article on Bloomberg, he expressed some frustration over the notoriety of investors like David Einhorn of Greenlight Capital, who has four times the assets under management that Macnguyen does, despite his fund underperforming Macnguyen’s Ivory Optimal since the beginning of 2009.

Curtis Macnguyen

“The only difference between me and Einhorn is that he’s higher profile and I’m purposely very low profile,” Mac­nguyen tells Bloomberg. “Plus, I’m supercompetitive and will only get better over time.”

According to the piece, Macnguyen avoids stocks termed as ‘hedge fund hotels’. These are companies that are very popular among hedge funds when the overall market looks good, but as soon as things look a bit shaky, the investors leave fast and in herds. According to his latest 13F filing, some of the top picks of his fund’s portfolio included popular choices of hedge fund managers such as eBay Inc (NASDAQ:EBAY), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Hertz Global Holdings, Inc. (NYSE:HTZ), Yahoo! Inc. (NASDAQ:YHOO) and American Airlines Group Inc (NASDAQ:AAL). According to our methodology, which is based on long holdings in companies exceeding market-caps of $1 billion, Ivory returned 4.3% during the first quarter based on its 61 qualifying holdings at the start of the quarter. This compares well with the S&P 500 ETF (SPY)’s returns of 0.9% during the same period. However, the issue remains whether Ivory will be found swimming naked when the tide goes out or not, in the sense of the popular analogy that Warren Buffett once drew.

Macnguyen initiated a stake in eBay Inc (NASDAQ:EBAY) during the fourth quarter with 2.06 million shares valued at $115.81 million. The e-commerce company, which is planning to spin off its payment arm PayPal sometime later this year represented 3.72% of the fund’s equity portfolio. Among the hedge funds that we track, 87 had invested $11.2 billion in the $69.87 billion market-cap company. It doesn’t really look like Ivory is ready for a flight of capital from this position, which was also one of the favorite stock picks among the billionaires that we track. Carl Icahn was one of them, as his fund Icahn Capital LP held some 46.27 million shares of eBay Inc (NASDAQ:EBAY) valued at $2.60 billion at the end of 2014.

Ivory’s stake in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) towards the end of the fourth quarter contained about 847,200 shares valued at $121.24 million. The $71.43 billion pharmaceutical company had 102 funds from our database invested in it, with an aggregate investment of $14.08 billion. Jeffrey Ubben’s Valueact Capital held the highest stake among those funds. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was recently backed by Bill Ackman of Pershing square to acquire the Botox maker Allergan. Even though the healthcare company failed in its attempt, Ackman made a healthy profit from the stake that it had acquired in Allergan.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!